Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 8:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 460 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Protein, High-Protein, and Control Clear all
Completed No phase listed Observational

Optical and Biochemical Biomarkers in Early Pancreatic Cancer

NCT03404661
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Synthetic Human Secretin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Sep 18, 2026, 8:23 AM EDT
Completed Phase 4 Interventional Results available

Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation

NCT03140631
View directory record Official record
Conditions
Atrial Fibrillation, Catheter Ablation
Interventions
Protamine Sulfate
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Sep 18, 2026, 8:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of High Protein Weight Loss for Seniors

NCT02730988
View directory record Official record
Conditions
Obesity, Weight Loss
Interventions
Weight Stable Group
Behavioral
Lead sponsor
Wake Forest University
Other
Eligibility
65 Years to 79 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 18, 2026, 8:23 AM EDT
Recruiting Phase 2 Interventional

High Dose Albumin in Refractory Ascites

NCT05867602
View directory record Official record
Conditions
Ascites
Interventions
Albumin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 18, 2026, 8:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dietary Intake Modifications to Protect Against Changes in Bone Metabolism

NCT01713634
View directory record Official record
Conditions
Bone Resorption
Interventions
Preflight, In-flight
Other
Lead sponsor
National Aeronautics and Space Administration (NASA)
Federal
Eligibility
Not listed
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2015 · Synced Sep 18, 2026, 8:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

High Quality Protein for Assisting With Weight Loss

NCT03085511
View directory record Official record
Conditions
Obesity
Interventions
Egg breakfast (EB), Weight Loss Counseling, Weight Loss Diet, Cereal Breakfast (CB)
Behavioral
Lead sponsor
Texas Tech University
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Sep 18, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

The CLEVER Study - Coreg And Left Ventricular Mass Regression

NCT00108082
View directory record Official record
Conditions
Hypertrophy, Left Ventricular
Interventions
carvedilol MR, atenolol, lisinopril
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
78
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 18, 2026, 8:23 AM EDT
Not listed Not applicable Interventional

N-Acetylcysteine for Patients With COPD and ChronicBronchitis

NCT01599884
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
Interventions
N-acetylcysteine, Oral acetylcysteine
Drug
Lead sponsor
Center for Veterans Research and Education
Other
Eligibility
40 Years to 85 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 15, 2012 · Synced Sep 18, 2026, 8:23 AM EDT
Completed Phase 4 Interventional Results available

Optima: Optimizing Prograf Therapy in Maintenance Allografts II

NCT00905515
View directory record Official record
Conditions
Kidney Transplantation
Interventions
cyclosporine, Prograf (Tacrolimus)
Drug
Lead sponsor
East Carolina University
Other
Eligibility
18 Years to 85 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Sep 18, 2026, 8:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

High Protein Breakfast on Weight Management and Glycemic Control in 'Breakfast-skipping' Teens

NCT03134014
View directory record Official record
Conditions
Breakfast, Appetitive Behavior
Interventions
Breakfast
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
15 Years to 21 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Sep 18, 2026, 8:23 AM EDT
Completed Phase 3 Interventional

Improving Pain Management and Long Term Outcomes Following High Energy Orthopedic Trauma (Pain Study)

NCT01789216
View directory record Official record
Conditions
Orthopaedic Fractures
Interventions
NSAID, Gabapentinoids, placebo
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 80 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
17
States / cities
Miami, Florida • West Palm Beach, Florida • Indianapolis, Indiana + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 18, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

LiveSMART Trial to Prevent Falls in Patients With Cirrhosis

NCT05794555
View directory record Official record
Conditions
Cirrhosis, Liver, Portal Hypertension
Interventions
Enhanced Usual Care, Lactulose, Investigator recommended exercise, TeleTai-Chi (virtual)
Behavioral · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Ann Arbor, Michigan • Philadelphia, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 18, 2026, 8:23 AM EDT
Terminated Phase 2Phase 3 Interventional

Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation

NCT00675714
View directory record Official record
Conditions
Burns
Interventions
Stable Isotope Infusion Study, Collection of blood and tissues, Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI, Humatrope, Ketoconazole, Oxandrolone, Propranolol, Oxandrolone and propranolol combined, Humatrope and propranolol combined, Placebo, Exercise--Hospital supervised intensive exercise program, Home exercise program
Procedure · Drug · Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 80 Years
Enrollment
1,126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Sep 18, 2026, 8:23 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY5625575 in Healthy Participants and in Participants With Inflammation (Elevated C-Reactive Protein)

NCT07801300
View directory record Official record
Conditions
Healthy Volunteers, C-Reactive Protein
Interventions
LY5625575, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Miami, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 18, 2026, 8:23 AM EDT
Completed Not applicable Interventional

Resveratrol-Leucine Metabolite Synergy in Pre-diabetes

NCT01593605
View directory record Official record
Conditions
Impaired Glucose Tolerance
Interventions
Resveratrol, resveratrol /HMB, Placebo treatment
Dietary Supplement · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Sep 18, 2026, 8:23 AM EDT
Recruiting Phase 1 Interventional

Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer

NCT07075120
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
Ipilimumab and Nivolumab, Stereotactic Body Radiotherapy (SBRT)
Drug · Radiation
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 18, 2026, 8:23 AM EDT
Not listed Phase 2 Interventional

Study of VF001-DP in Patients With Chronic Venous Leg Ulcers

NCT02973893
View directory record Official record
Conditions
Ulcer, Leg Ulcer, Varicose Ulcer, Pathologic Processes, Skin Ulcer, Skin Diseases, Vascular Diseases, Cardiovascular Diseases
Interventions
Placebo, VF001-DP LD, VF001-DP HD
Biological
Lead sponsor
Factor Therapeutics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
17
States / cities
Carlsbad, California • Fresno, California • Laguna Hills, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Sep 18, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of IVX-A12 in Healthy Older Adults

NCT05664334
View directory record Official record
Conditions
Healthy
Interventions
IVX-121, IVX-241, Placebo, MF59®
Biological · Other
Lead sponsor
Icosavax, Inc.
Industry
Eligibility
60 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
4
States / cities
Hollywood, Florida • Atlanta, Georgia • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Sep 18, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis

NCT02471144
View directory record Official record
Conditions
Chronic Severe Plaque-type Psoriasis
Interventions
Experimental : Secukinumab low dose, Experimental: Secukinumab high dose, Placebo Comparator: Secukinumab Placebo, Active Comparator: Etanercept
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Sep 18, 2026, 8:23 AM EDT
Terminated Phase 3 Interventional Results available

Phase 3 IGIV, 10% in Alzheimer´s Disease

NCT01524887
View directory record Official record
Conditions
Alzheimer´s Disease
Interventions
Immune Globulin Intravenous (Human), 10% Solution, Human albumin 0.25%
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
50 Years to 89 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 18, 2026, 8:23 AM EDT
Completed Not applicable Interventional Results available

Physiologic Response to Glucagon at Varying Insulin Levels

NCT01483651
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Glucagon, Insulin
Drug
Lead sponsor
Legacy Health System
Other
Eligibility
21 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Sep 18, 2026, 8:23 AM EDT
Completed Phase 2 Interventional

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

NCT06340360
View directory record Official record
Conditions
Alopecia Areata
Interventions
Rezpegaldesleukin, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Northridge, California • Atlanta, Georgia • Gurnee, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 18, 2026, 8:23 AM EDT
Completed Phase 2 Interventional

New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma

NCT00001335
View directory record Official record
Conditions
Ewing's Sarcoma, Neuroblastoma, Rhabdomyosarcoma
Interventions
ADR-529, Topotecan, G-CSF
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 18, 2026, 8:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Diet Modulation of Bacterial Sulfur and Bile Acid Metabolism and Colon Cancer Risk

NCT03550885
View directory record Official record
Conditions
Colorectal Cancer
Interventions
High taurine and saturated fat diet, Low in taurine and saturated fat diet
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
45 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 18, 2026, 8:23 AM EDT